The Chinese Cephalexin market got a little boost of 0.8% in January 2026 - owing largely to steady buying from international customers in the early months & steady production kicking in at Shanghai-area fermentation plants. Cephalexin prices ticked up too, because public sector tenders in India & Brazil got back on track after the holiday break, & that soaked up the usual number of exports. The price didn't get pinched too much by rising raw material costs for 7-ADCA and phenylglycine derivatives - mainly because coal-fired steam costs & environmental compliance fees added a bit to the costs. Domestic sales didn't budge, with hospitals keeping their normal antibiotic orders going, but retail and formulator demand was pretty much the same. Manufacturers had enough stock to export & meet orders with a bit to spare, so suppliers were able to hold their ground without making the supply too tight. Looking forward to February, market analysts think the Cephalexin price trend will start to ease. Next month's buying is expected to slow down, with buyers taking a step back to figure things out. Slow demand from formulators further down the line & exporters having enough stock to sell, are likely to start to take some of the pressure off and calm things down a bit - so price movements should be slightly bearish for the upcoming weeks.
